Author:
Dang Vica,Jamieson Frances B,Wilson Sarah,Rawte Prasad,Crowcroft Natasha S,Johnson Karen,Tsang Raymond S W,Deeks Shelley L
Abstract
Abstract
Background
Invasive meningococcal disease (IMD) caused by serogroup B is the last major serogroup in Canada to become vaccine-preventable. The anticipated availability of vaccines targeting this serogroup prompted an assessment of the epidemiology of serogroup B disease in Ontario, Canada.
Methods
We retrieved information on confirmed IMD cases reported to Ontario’s reportable disease database between January 1, 2000 and December 31, 2010 and probabilistically-linked these cases to Public Health Ontario Laboratory records. Rates were calculated with denominator data obtained from Statistics Canada. We calculated a crude number needed to vaccinate using the inverse of the infant (<1 year) age-specific incidence multiplied by expected vaccine efficacies between 70% and 80%, and assuming only direct protection (no herd effects).
Results
A total of 259 serogroup B IMD cases were identified in Ontario over the 11-year period. Serogroup B was the most common cause of IMD. Incidence ranged from 0.11 to 0.27/100,000/year, and fluctuated over time. Cases ranged in age from 13 days to 101 years; 21.4% occurred in infants, of which 72.7% were <6 months. Infants had the highest incidence (3.70/100,000). Case-fatality ratio was 10.7% overall. If we assume that all infant cases would be preventable by vaccination, we would need to vaccinate between 33,784 and 38,610 infants to prevent one case of disease.
Conclusions
Although rare, the proportion of IMD caused by serogroup B has increased and currently causes most IMD in Ontario, with infants having the highest risk of disease. Although serogroup B meningococcal vaccines are highly anticipated, our findings suggest that decisions regarding publicly funding serogroup B meningococcal vaccines will be difficult and may not be based on disease burden alone.
Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. Brown EM, Fisman DN, Drews S, Doman S, Rawte P, Brown S, Jamieson F: Epidemiology of invasive meningococcal disease with decreased susceptibility to penicillin in Ontario, Canada, 2000 to 2006. Antimicrob Agents Chemother. 2010, 54 (3): 1016-21. 10.1128/AAC.01077-09.
2. Tsang RSW, Squires SG, Tam TWS: Characterization of Neisseria meningitidis strains isolated from invasive meningococcal disease cases in Canada in 2001. Can J Microbiol. 2003, 49: 633-8. 10.1139/w03-074.
3. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM: Meningococcal disease. N Engl J Med. 2001, 344: 1378-88. 10.1056/NEJM200105033441807.
4. Navarro C, Deeks SL, Medaglia A, Tsang RSW: Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2004, through 31 Dec, 2005. Can Commun Dis Rep. 2007, 33 (10): 1-15.
5. Public Health Agency of Canada: Guidelines for the Prevention and Control of Meningococcal Disease. Can Commun Dis Rep. 2005, 31 (S1): 1-20.
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献